The Hidden Cost of Redesigning a Medical Device Late in Development

In medical device development, redesigns are often viewed as a normal part of the engineering process.

And to some extent, they are.

Iterating, refining, and improving a product are essential steps in building a reliable medical device. But there is a major difference between planned iteration during early development and redesigning a product late in the process.

Late-stage redesigns are where costs begin increasing rapidly.

A small design change that may seem manageable on the surface can trigger manufacturing delays, additional testing, documentation updates, supplier changes, and even regulatory setbacks.

This is why one of the most expensive moments in medical device development is discovering a critical issue after significant progress has already been made.

Industry studies suggest that nearly 70–80% of a product’s lifecycle cost is influenced during the design phase itself, long before manufacturing begins.

The hidden cost is not just the redesign itself.

It is the chain reaction that follows.

Why Late-Stage Redesigns Become So Expensive

Early in development, engineering changes are relatively flexible.

CAD models can be adjusted quickly. Prototype modifications are easier to implement. Teams are still exploring different approaches and validating concepts.

But as development progresses, the product becomes increasingly interconnected.

By later stages, the device may already involve:

• Finalized assemblies

• Supplier coordination

• Tooling preparation

• Manufacturing planning

• Testing procedures

• Documentation workflows

  
  

At this point, even a small change can affect multiple systems simultaneously.

For example, modifying a component’s geometry may also require:

• Tooling adjustments

• Assembly updates

• Tolerance re-evaluation

• Supplier communication

• Repeat verification testing

  
  

The further development progresses, the larger the impact of each change becomes.

According to product development estimates across regulated industries, engineering changes introduced late in development can cost 10–100 times more compared to changes made during early concept stages.

This is why redesign costs increase disproportionately during later stages.

The Difference Between Early Iteration and Late Redesign 

Iteration is a healthy part of product development.

In fact, most successful medical devices go through multiple design refinements before reaching production.

But effective iteration usually happens early, when the product is still flexible. Late redesigns are different because they often happen after assumptions have already been locked into manufacturing, validation, or workflow planning.

For example:

• A usability issue discovered during validation

• An assembly challenge identified during pilot manufacturing

• An unexpected material behavior during repeated sterilization

• Alignment instability appearing after repeated use

  
  

These problems may require deeper structural changes than initially expected.

And unlike software, hardware redesigns rarely stay isolated.

Changing one part often affects:

• Surrounding components

• Assembly interactions

• Load distribution

• Manufacturability

• Usability

  
  

This interconnectedness is what makes late-stage hardware redesign particularly expensive in medtech.

Manufacturing Complications Increase Quickly

One of the biggest hidden costs of redesign appears during manufacturing preparation. A prototype may work successfully in limited testing, but manufacturing environments expose issues prototypes often hide.

For example:

• Assembly may take longer than expected

• Components may require manual adjustment

• Tolerance variation may reduce consistency

• Parts may become difficult to align repeatedly

  
  

At low volume, engineers can sometimes compensate manually.

At production scale, these inefficiencies become operational problems.

Even an additional 20–30 seconds in assembly time per unit can create significant production bottlenecks when manufacturing thousands of devices.

Even a small increase in assembly time can significantly affect:

• Production throughput

• Labor requirements

• Manufacturing cost

• Delivery timelines

  
  

This is why manufacturing teams often push for Design for Manufacturing (DFM) much earlier than development teams initially expect.

Research in manufacturing engineering suggests that strong DFM practices can reduce production costs by 20–50% depending on product complexity.

A product designed only for functionality may still struggle during scalable production.

Supplier and Tooling Dependencies

As products move closer to production, supplier relationships and tooling investments become more established. This increases the impact of redesigns even further.

For example, changing:

• Materials

• Dimensions

• Fastening methods

• Assembly geometry

  
  

May require:

• New tooling

• Supplier requalification

• Updated machining processes

• Revised procurement strategies

  
  

These changes affect not only engineering teams but also operations, manufacturing, and project timelines.

In some cases, tooling modifications alone can delay development significantly.

Injection molding tooling revisions, for example, may add several weeks or even months to development timelines depending on complexity and supplier availability.

And because medical devices often involve strict validation processes, these delays can cascade into additional testing and documentation requirements.

Validation and Regulatory Impact 

One of the most underestimated consequences of late redesigns is regulatory impact.

Medical device development is heavily documentation-driven.

By validation stage, teams may already have:

• Risk management documentation

• Usability studies

• Verification reports

• Test protocols

• Manufacturing documentation

A redesign introduced at this stage may require portions of this work to be repeated.

For example:

• Updated testing plans

• Revised risk analysis

• Repeat verification

• Additional validation activities

• Documentation revisions

  
  

This creates both financial and timeline pressure.

Industry estimates suggest that redesigns discovered after verification or validation can delay commercialization timelines by anywhere between 3–9 months depending on device complexity and regulatory pathway.

And unlike early-stage iteration, these delays often affect multiple departments simultaneously.

The Hidden Cost of Delayed Learning 

Another major cost of late redesigns is delayed learning.

When critical engineering questions are not explored early enough, teams often discover important problems much later than they should have.

For example:

• Manufacturability concerns

• Usability friction

• Material instability

• Assembly inefficiencies

• Workflow interruptions

  
  

These issues are easier and cheaper to solve earlier in development.

But when teams postpone testing or validation of these assumptions, the cost of learning increases dramatically later.

In many ways, product development is a process of reducing uncertainty. The earlier uncertainty is identified, the lower the overall development risk tends to be.

Why Usability Problems Often Trigger Redesigns

Usability issues are among the most common causes of late-stage redesign in medtech.

A device may function technically while still creating problems in real clinical environments.

Research shows clinicians can spend nearly 15–20% of their workflow time interacting with medical equipment, setup processes, and interfaces.

Even small inefficiencies therefore create meaningful operational impact over time.

For example:

• Grip discomfort during repeated use

• Cleaning complexity

• Workflow interruption

• Difficult setup procedures

• Poor accessibility during operation

  
  

These problems may not appear during controlled engineering reviews.

But once devices enter realistic clinical workflows, small inefficiencies become much more visible. And because usability directly affects clinician adoption, these issues often cannot be ignored. As a result, teams may be forced into redesigns much later than expected. This is why human factors and workflow evaluation are increasingly integrated earlier into medical device development.

Material Decisions Can Create Long-Term Problems

Material selection is another area where late-stage redesigns become expensive.

A material that performs well during early testing may behave differently under:

• Repeated sterilization

• Manufacturing stress

• Long-term wear

• Environmental exposure

• Continuous handling

  
  

For example:

• Plastics may deform

• Coatings may wear inconsistently

• Thermal expansion may affect alignment

• Surfaces may degrade over time

  
  

When these issues appear late, redesign may involve far more than simply changing the material itself.

The product geometry, tolerances, manufacturing process, and assembly strategy may also need adjustment. This is why material scalability and long-term reliability should be evaluated early whenever possible.

The Importance of Thinking Beyond the Prototype

One of the biggest mistakes in medtech development is focusing only on getting the prototype to work.

A working prototype is important.

But commercialization requires much more than functionality.

The product must also be:

• Manufacturable

• Repeatable

• Scalable

• Serviceable

• Usable

• Reliable over time

  This requires broader engineering thinking much earlier in development.

The most successful medical device teams do not separate:

• Engineering

• Manufacturing

• Usability

• Scalability

  
  

Instead, they evaluate these factors together throughout development.

How Early Engineering Reduces Redesign Risk

The best way to reduce expensive redesign cycles is not by avoiding iteration entirely.

It is by shifting important learning earlier.

This often includes:

• Early DFM evaluation

• Workflow testing

• Assembly planning

• Usability feedback

• Material analysis

• Repeated-use testing

  
  

The goal is to identify instability before systems become too interconnected.

Because once tooling, validation, manufacturing coordination, and regulatory documentation are active, even small changes become difficult to isolate.

This is why experienced product development teams place heavy emphasis on early engineering structure.

Not because redesign is bad, but because late redesign is expensive.

Conclusion 

Redesign is a natural part of medical device development.

But the timing of redesign matters significantly.

Changes introduced late in development often create hidden costs far beyond engineering alone. They affect manufacturing, suppliers, validation, usability, timelines, documentation, and commercialization planning simultaneously.

A prototype proving functionality is only one stage of the journey.

Building a scalable, manufacturable, and reliable medical device requires thinking about production realities much earlier than many teams initially expect.

The most successful medical device products are rarely the ones with the fewest iterations.

They are the ones that identify critical problems early, before redesign becomes operationally expensive.

Because in medtech, the hidden cost of late redesign is usually not the design change itself.

It is everything connected to it.

Schedule a call with our team to walk through your requirements and understand the most practical way to move forward.